🟢 Telix Pharmaceuticals is trading 5.49% up in pre-market as Nasdaq and S&P 500 rebound

Telix Pharmaceuticals is trading 5.49% up in pre-market at $12.48 after a broader pre-market recovery lifted major U.S. indexes.

• Nasdaq Composite rose 1.04%, while the S&P 500 gained 0.80%.
• The stock had a volatile week after Pixclara received FDA approval on September 14, driving earlier gains before profit-taking.
• No new company-specific announcement was identified on September 17; the rebound appears primarily linked to improved market sentiment.